Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070996" target="_blank" >RIV/65269705:_____/19:00070996 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14740/19:00109738

Výsledek na webu

<a href="https://www.nature.com/articles/s41375-018-0322-7" target="_blank" >https://www.nature.com/articles/s41375-018-0322-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-018-0322-7" target="_blank" >10.1038/s41375-018-0322-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors

Popis výsledku v původním jazyce

Chronic lymphocytic leukemia (CLL) displays remarkable clinical heterogeneity, likely attributed to the underlying biological diversity [1]. This claim is supported by the fact that certain immunogenetic and/or genomic features identify subgroups of CLL patients with distinct prognosis and outcome [2,3,4]. Indeed, determination of the somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) genes expressed by the clonotypic B cell receptor (BcR) and screening for aberrations οf the TP53 gene are nowadays considered essential for clinical decision making [5]. A cautionary note appears warranted when utilizing biomarkers, where the prognosis is usually assessed assuming stable predictability over the disease course; this hypothesis, however, is often unrealistic as it concerns genomic aberrations [6, 7]. Therefore, arguably, the prognostic power of a given biomarker may, instead, heavily depend on the time distance from diagnosis.

Název v anglickém jazyce

Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors

Popis výsledku anglicky

Chronic lymphocytic leukemia (CLL) displays remarkable clinical heterogeneity, likely attributed to the underlying biological diversity [1]. This claim is supported by the fact that certain immunogenetic and/or genomic features identify subgroups of CLL patients with distinct prognosis and outcome [2,3,4]. Indeed, determination of the somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) genes expressed by the clonotypic B cell receptor (BcR) and screening for aberrations οf the TP53 gene are nowadays considered essential for clinical decision making [5]. A cautionary note appears warranted when utilizing biomarkers, where the prognosis is usually assessed assuming stable predictability over the disease course; this hypothesis, however, is often unrealistic as it concerns genomic aberrations [6, 7]. Therefore, arguably, the prognostic power of a given biomarker may, instead, heavily depend on the time distance from diagnosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

1801-1805

Kód UT WoS článku

000473724900022

EID výsledku v databázi Scopus

2-s2.0-85060671726